Comparative Pharmacology
Head-to-head clinical analysis: PYRIDOSTIGMINE BROMIDE versus RAZADYNE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PYRIDOSTIGMINE BROMIDE versus RAZADYNE.
PYRIDOSTIGMINE BROMIDE vs RAZADYNE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible acetylcholinesterase inhibitor, prolonging the action of acetylcholine at nicotinic and muscarinic receptors.
Galantamine is a reversible competitive acetylcholinesterase inhibitor and an allosteric modulator of nicotinic acetylcholine receptors, enhancing cholinergic function in the central nervous system.
Oral: 60-120 mg every 3-4 hours (max 360 mg/day). Intravenous: 0.1-0.25 mg/kg IV (max 10 mg per dose) for reversal of nondepolarizing neuromuscular blockade, given with glycopyrrolate or atropine. Intramuscular: 0.2-1 mg for postoperative urinary retention.
Initial dose 8 mg/day PO (4 mg twice daily) for 4 weeks; increase to 16 mg/day (8 mg twice daily) for at least 4 weeks; maintenance 16-24 mg/day (12 mg twice daily). Extended-release: initial 8 mg PO once daily; after 4 weeks increase to 16 mg once daily; if tolerated, may increase to 24 mg once daily.
None Documented
None Documented
Terminal half-life: 1-2 hours (prolonged in renal impairment; up to 6 hours in anuria)
Terminal elimination half-life is approximately 7-8 hours in healthy adults, allowing twice-daily dosing; unchanged in mild to moderate hepatic impairment but prolonged in severe hepatic impairment.
Renal: 70-90% unchanged; biliary/fecal: minor (<10%)
Renal excretion of unchanged drug accounts for approximately 20-25% of the dose; the remainder is metabolized by the liver and excreted as metabolites in urine (about 95% total) and feces (about 5%).
Category A/B
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor